07:53 AM EDT, 08/20/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) has obtained exclusive worldwide rights to develop and commercialize Saniona's experimental epilepsy drug, SAN2355, the companies said Wednesday.

Saniona will receive an upfront payment of $42.5 million, with potential additional payments totaling over $1 billion, including development, regulatory, and commercial milestone payments, as well as royalties on future sales, the companies said.